Royalty Pharma annual ebitda
2023
2024
Royalty Pharma EBITDA Growth & History (RPRX)
Royalty Pharma's calculated EBITDA was $1.29B for fiscal 2024.
View full Royalty Pharma company overviewRoyalty Pharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $1.29B | −$199.7M | −13.38% |
| 2023 | 2023-12-31 | $1.49B | — | — |
Royalty Pharma quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Royalty Pharma ebitda trends
Across the available reported history, Royalty Pharma's ebitda decreased from $1.49B to $1.29B, a change of −$199.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma filings at SEC.gov ↗